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Virion morphologyscently released human immunodeﬁciency virus type 1 (HIV-1) particles is
responsible for the cleavage of the viral polyproteins Gag and Gag–Pol into their constituent parts, which
results in the subsequent condensation of the mature conical core surrounding the viral genomic RNA.
Concomitant with viral maturation is a conformational change in the packaged viral RNA from a loosely
associated dimer into a more thermodynamically stable form. In this study we used suboptimal
concentrations of two protease inhibitors, lopinavir and atazanavir, to study their effects on Gag polyprotein
processing and on the properties of the RNA in treated virions. Analysis of the treated virions demonstrated
that even with high levels of inhibition of viral infectivity (IC90), most of the Gag and Gag–Pol polyproteins
were processed, although slight but signiﬁcant increases in processing intermediates of Gag were detected.
Drug treatments also caused a signiﬁcant increase in the proportion of viruses displaying either immature or
aberrant mature morphologies. The aberrant mature particles were characterized by an electron-dense
region at the viral periphery and an electron-lucent core structure in the viral center, possibly indicating
exclusion of the genomic RNA from these viral cores. Intriguingly, drug treatments caused only a slight
decrease in overall thermodynamic stability of the viral RNA dimer, suggesting that the dimeric viral RNAwas
able to mature in the absence of correct core condensation.
Published by Elsevier Inc.Introduction
The production of infectious human immunodeﬁciency virus type
1 (HIV-1) particles from an infected cell is not complete upon release
of budding particles from the cell membrane. In fact, a nascently
released virion is immature and noninfectious, consisting of a lipid
bilayer and an electron-dense ring surrounding an electron-lucent
interior (Palmer and Goldsmith, 1988). Soon after release, the
immature particle undergoes a global rearrangement event, the
electron-dense ring is lost and an electron-dense conical core is
formed (Palmer and Goldsmith, 1988); these modiﬁcations of the viral
particle are called maturation. Maturation is an essential step to
generate infectious virus and is initiated by the activity of the virally
encoded protease (Peng et al., 1989). The protease is packaged into
viral particles as part of the Gag–Pol polyprotein (reviewed in
Swanstrom and Wills, 1997; Adamson and Freed, 2007). The protease
ﬁrst cleaves the polyprotein to release itself and then performs annc.ordered cascade of proteolytic cleavage events to break down the
polyproteins Gag and Gag–Pol into their constituent proteins (Fig. 1)
(Pettit et al., 2004; Pettit et al., 2005b).
Concomitant with maturation of the proteinaceous constituents of
the viral particle, the viral genome also undergoes rearrangement.
The genomic RNA within nascently released virions is found as a
loosely associated dimeric species that migrates by native electro-
phoresis as two distinct bands, corresponding to a thermodynami-
cally unstable dimer and a monomer (Fu et al., 1994; Fu and Rein,
1993; Stoltzfus and Snyder, 1975). However, after maturation of the
virus, the RNA is found as a tight dimer of greater thermodynamic
stability compared with that of immature particles (Fu et al., 1994).
The process of RNA maturation is dependent on the initial cleavage
event between spacer peptide 1 (SP1) and nucleocapsid (NC) of Gag,
which is one of the steps that results in the release of NC, a protein
that demonstrates high levels of chaperone activity in vitro (Feng et
al., 1996; Shehu-Xhilaga et al., 2001). Thus, maturation of the virus
particle into an infectious virion is dependent on proteolytic cleavage
of Gag by the protease, and is associated with core condensation and
RNA stabilization. Proteolytic cleavage appears to be necessary but
not sufﬁcient for dimeric RNA maturation. In HIV-1 late-domain
Fig. 1. An ordered cascade of Gag polyprotein proteolytic cleavage. The activity of the
viral protease (indicated by an arrow) is initiated during viral budding from the infected
cell. The full-length Gag (p55) is initially cleaved at the SP1–NC border (A) releasing
MA–CA–SP1 (p41) and NC–SP2–p6 (p15) (B). These processing intermediates undergo
another round of cleavage events, which release MA (p17), CA–SP1 (p25), NC (p7), SP2
(p1) and p6 (C). The ﬁnal processing event, which is required for successful maturation
of the viral particle, separates SP1 (p2) from CA (p24) (D).
Fig. 2. Inhibition of HIV-1 infectivity by the protease inhibitors lopinavir and atanazavir.
Cells were transfected with an HIV-1 vector plasmid or a similar vector containing a
protease active-site mutant (PR−) and a plasmid expressing HIV-1 Env. Lopinavir (LPV)
or atazanavir (ATV) were added posttransfection at various concentrations. Twenty-
four hours later virus was harvested and used to infect a TZM-bl reporter cell line, the
resulting luciferase activity was used as an indicator for the viral infectivity. (A) The
effects of protease inhibitors on HIV-1 infectivity. Luciferase output was measured and
results are represented as a percentage of that obtained with no protease inhibitor
(WT). (B) Samples in which the virus infectivities were inhibited by the protease
inhibitors at 50k (IC50) or 90k (IC90) were used in this study. Results shown are the
average of triplicate samples from one representative experiment; variation among the
triplicates samples was small (generally within 10k of the average values).
153M.D. Moore et al. / Virology 379 (2008) 152–160mutant viruses lacking the PTAP motif in p6 of Gag (PTAP−), the Gag
polyprotein is largely processed (Huang et al., 1995); however, the
conical virion core is absent (Demirov et al., 2002) and the dimeric
RNA is less thermodynamically stable than that of wild-type viruses
(Fu et al., 2006). From these studies, we hypothesize that the
condensation and formation of the virion core are important for viral
RNA maturation.
The development of potent HIV-1 protease inhibitors was a major
step toward the successful treatment of HIV-1 infection (Balter, 1996).
When used in combination with the existing nucleoside and
nonnucleoside reverse transcriptase (RT) inhibitors, protease inhibi-
tors allowed for the establishment of the ﬁrst highly active
antiretroviral regimens (Ho et al., 1995; Wei et al., 1995). The
currently Food and Drug Administration (FDA) approved protease
inhibitors bind to the active site of the protease and prevent it from
functioning within released particles (Louis et al., 2007); conse-
quently, these drugs inhibit the maturation process and render the
virus noninfectious (Kaplan et al., 1993). Interestingly, it was
previously shown that the level of inhibition of the proteolytic
cleavage pathway does not correlate with its effects on the replication
ﬁtness of the virus (Kaplan et al., 1993). Treated virions were found to
have altered morphology, but the large majority of proteins within the
particles were cleaved. Based on this ﬁnding, it was suggested that
maturation is not simply a product of Gag cleavage into its constituent
proteins but rather is an ordered process that is easily disrupted by
the addition of protease inhibitors (Kaplan et al., 1993; Pettit et al.,
2005a). Maturation of the viral RNA is linked to the cleavage of Gag
(Fu et al., 1994), and dependent on the SP1/NC cleavage event (Shehu-
Xhilaga et al., 2001); therefore, it was of interest to determine the
effects of protease inhibitors on maturation of the genomic RNA. In
this study we treated virus-producing cells with suboptimal con-
centrations of two different FDA-approved protease inhibitors,
lopinavir and atazanavir. Using these treated viruses, we conﬁrmed
the previous observations regarding the disparity between proteolytic
cleavage and virion infectivity (Kaplan et al., 1993). Furthermore,
protease inhibitor treatment resulted not only in an increased fraction
of immature particles but also in the generation of a large proportion
of mature particles with aberrant morphology. Intriguingly, the
thermodynamic stability of the drug-treated virion RNA was only
slightly lower than that of untreated viruses, suggesting that RNA in
viruses of aberrant morphology had also undergone maturation. This
study reveals how protease inhibitors affect the infectivity and
morphology of the virus and also provides insights into the process
of RNA maturation.Results
Effects of protease inhibitors on HIV-1 replication
Using a single-cycle assay, we evaluated the effects of protease
inhibitors on HIV-1 replication. Plasmid pON-fHIG (Rhodes et al.,
2005), which encodes an HIV-1 vector expressing gag–pol, tat, and
rev, and plasmid pIIINL(AD8)env (Huang et al., 1995), which expresses
HIV-1 env, were cotransfected into 293T cells to produce virions for
study. Various concentrations of the protease inhibitors lopinavir and
atazanavir were added to transfected 293Tcells at suboptimal levels to
inhibit the viral protease. The effects of these protease inhibitors were
ﬁrst evaluated using a single-cycle reporter cell line, TZM-bl (Derdeyn
et al., 2000; Wei et al., 2002), which contains a luciferase gene under
the transcriptional control of an HIV-1 promoter. The expression of the
luciferase gene in TZM-bl cells is normally suppressed due to the lack
of Tat, but is greatly enhanced upon infection of HIV-1 and expression
of Tat. Therefore, the level of luciferase expressed from these cells
provides a quantiﬁcation of the infectious viral titer within the viral
supernatants. We included two controls in each experiment: a virus
stock without protease inhibition (WT), which was produced in the
absence of protease inhibitors, and a virus stock with complete
inhibition of the viral protease (PR−), which was derived from a D25N
active-site mutant virus (Kohl et al., 1988). A drug kill curve was
performed for each experimental set (Fig. 2A) to accommodate the
inherent variation in the level of inhibition generated by the drugs.
Virus samples in which infectivities were inhibited by protease
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luciferase output from the TZM-bl cells (Fig. 2B), were selected for
further analysis.
Effects of protease inhibitor treatment on proteolytic processing of viral
polyproteins
To assess the extent of proteolytic cleavage in the presence of the
protease inhibitors, we performed western analyses of the virion
proteins and examined the potential processing defect of each sample
by quantifying the intensities of various bands representing different
processing products. In line with previous studies, we detected a
slight decrease in overall Gag processing (Fig. 3A) and none in RT
processing (Fig. 3B) (Kaplan et al., 1994; Kaplan et al., 1993). The
drug-treated virions contained close to wild-type levels of released
capsid (CA, p24) and similar levels of free RT with the correct p66 to
p51 ratio of 1:1. Using an endogenous RT assay, we also measured the
activity of the processed RT and found it to be the same across
treatment groups (data not shown) except for PR− virus, which had
undetectable levels as indicated by the absence of the p66 and p51
bands on the western blot (Fig. 3B). The only defects that could be
quantiﬁed (shown in Fig. 3C) within these western blots were a slight
increase in unprocessed CA–SP1 (p25), a more pronounced increase
in unprocessed Matrix (MA)–CA (p41), and the appearance of anFig. 3. Effects of suboptimal protease inhibition on proteolytic cleavage of Gag and Gag–Pol. Th
harvested and concentrated by ultracentrifugation. The viral pellet was then analyzed fo
polyprotein. Human-derived anti-HIV antibodies were used to identify the major Gag-derive
The corresponding sizes of the HIV-1 proteins are shown to the right [p55 (Gag), p47 (potent
cleavage of the pol gene product. The membrane was also treated with a rabbit anti-RT antib
cleavage products. The intensities of the major Gag bands were quantiﬁed using an Odyss
subtracting by the median border method, are plotted as the percentage of each band to the t
different sample sets, from a total of three independent experiments; means and standardadditional species that possibly represents p47 (MA–CA–SP1–NC–
SP2), which would be the result of removing the p6 domain from the
p55 Gag precursor.
The morphology of protease inhibitor-treated virions
Upon release, most HIV-1 virions appear to be ~110-nm-diameter
spherical particles with an electron-dense ring at the periphery
surrounding a translucent core. Shortly after release, the free CA,
cleaved from the Gag polyprotein by the viral protease, associates into
a conical core structure at the center of the particle, and the electron-
dense ring at the periphery is lost (Palmer and Goldsmith, 1988).
These visible structural alterations are part of the virion maturation
process, which is essential to viral replication. To measure the effects
of protease inhibitors on budding and maturation, we analyzed both
cell-associated and cell-free virions by electron microscopy (EM). By
observing the virions in association with the transfected cells, we
were able to obtain a snapshot of the process of particle release, which
includes the budding process as well as maturation. However, the
ratio of immature to mature particles is biased toward the immature
phenotype, some of which may eventually mature. The analysis of
cell-free virions partially overcomes this bias and provides a better
representation of the overall ability of the virus to complete the
maturation process.e virus released from transfected cells with or without protease inhibitor treatmentwas
r its protein constituents by western blotting. (A) Proteolytic processing of the Gag
d products. A size marker is also shownwith the apparent molecular mass of each band.
ially MA–CA–SP1–NC–SP2), p41 (MA–CA–SP1), p25 (CA–SP1), p24 (CA)]. (B) Proteolytic
ody to observe the two RT bands, p66 and p51. (C) Quantiﬁcation of the Gag polyprotein
ey infrared imaging system. Integrated intensities, with the background of each band
otal signal intensity measured from all bands. The data represent the results from seven
error are shown.
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difﬁcult to detect viral particles associated with untreated 293T cells
and no budding intermediates were evident, even though these cells
were actively producing viruses (Fig. 4B). In contrast, increasing the
concentration of protease inhibitor resulted in an increase in both the
number of viral particles at the cell periphery and the number of
budding intermediates (Fig. 4B). Quantiﬁcation of the percentage of
cell-associated viral particles observed to be budding suggests a delay
in the virion release process when either protease inhibitor was used
at either concentration (Fig. 4B). However, when measuring the total
p24 count in the supernatants by ELISA, we could not detect a
signiﬁcant decrease in viral release among drug-treated groups (data
not shown). Thus, the possible decrease in budding kinetics was
insufﬁcient to cause a particle-release defect over a 24-hour period.
Similarly, we observed more cell-associated particles in the PR–
samples, although PR− virions were still released and similar levels of
Gag proteins were detected by western analyses. Western analyses
were used because our p24 ELISA did not detect the unprocessed Gag.
These results conﬁrmed an earlier report demonstrating that althoughFig. 4. Effects of HIV-1 protease inhibition on viral release. The virus released from 293T c
without protease inhibitor exposure. (A) Representative electron micrographs of virions in as
still in the process of budding and therefore attached to the cell membrane are represented a
each treatment group. The results are plotted as a percentage of the total particle count (althe protease activity is involved in the budding process, it is not
essential (Kaplan et al., 1994).
Quantitative analysis of the viral morphology (Fig. 5A) at both the
early time points during or soon after release (cell-associated samples,
Fig. 5B) and later time points (cell-free samples, Fig. 5C) demonstrates
that the protease inhibitor treatment caused a delay inmaturation and
resulted in the presence of morphologically aberrant viruses. Upon
treatment at IC90 concentrations, the delayed maturation process was
evident by comparing the percentage of total particles with immature
morphology in the cell-associated counts with that of cell-free
preparations. For the untreated and IC50 treatment groups, the
relative ratios of immature to mature (Figs. 5B and C, the white
portion of bar compared with the black and gray portions) remain the
same from cell-associated to cell-free counts. In contrast, higher drug
concentrations (IC90) display many more immature particles in the
cell-associated counts compared with the untreated control. More-
over, the overrepresentation of immature particles is lost when
observing IC90-treated cell-free virions, demonstrating that although
maturation was delayed, it was not prevented.ells transfected with an HIV-1 expression plasmid was observed by EM either with or
sociation with the cell periphery are shown for each treatment group. (B) Viral particles
s a percentage of the total number of viral particles counted within the cell periphery for
so shown).
Fig. 5. Effects of HIV-1 protease inhibition on viral maturation. (A) Electron micrographs of individual viral particles are shown grouped according to their morphology. Each viral
particle was scored as either immature, containing an electron-dense ring (or partial ring) around an electron-lucent core; mature regular, lacking an electron-dense ring but
containing an electron-dense core; or mature eccentric, lacking both an electron-dense ring and an electron-dense core. Note that some of the mature eccentric cores appear to
contain a core structure but it is electron-lucent; the electron-dense region in these particles is sequestered to the side of the virion, as it is in all the mature eccentric particles.
Quantiﬁcation of the viral particles found within the cell periphery (B), and cell-free virions (C), into three groups according to their morphology. The results are plotted as a
percentage of the total particle count (also shown).
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drug-treated virions that underwent maturation, as deﬁned by a loss
of the electron-dense ring of the immature viruses, did so in an
aberrant manner. Most of the wild-type viruses had a mature
appearance, containing a condensed core in or near the center of
the particle (Fig. 5A, mature regular); a small percentage of the
particles had an immature phenotype (Fig. 5A, immature) with an
electron-dense ring at the periphery of the particles, a morphology
characteristic of PR− viruses. However, in addition to these mature and
immature phenotypes, many of the particles in the drug treatment
groups also appeared to have an aberrant mature phenotype (Fig. 5A,
mature eccentric). These particles no longer had the electron-densering of the immature viruses but instead displayed an electron-dense
patch on one side. Additionally, many of these particles appeared to
contain bcoresQ that were electron-lucent and did not resemble the
electron-dense cores of the wild-type viruses; this observation
suggests these bcoresQ might be empty and lack the genomic RNA.
The proportion of these aberrant viruses was signiﬁcantly higher in
cell-free virion samples treated with either protease inhibitor at
either concentration compared with untreated, wild-type samples
(Pb0.001 in all four comparisons of wild-type versus drug-treated
samples, Chi square statistic) (Fig. 5C). In fact, quantiﬁcation of the
mature particles with normal morphology correlated to the infecti-
vity data (Fig. 5C black portion of the bar versus Fig. 2B), conﬁrming
157M.D. Moore et al. / Virology 379 (2008) 152–160that the establishment of a properly condensed electron-dense core is
essential to the infectivity of mature HIV-1 particles.
Stability of RNA from protease inhibitor-treated virions
In a previous report, we showed that late-domain mutant (PTAP−)
viruses contained dimeric RNA that was less thermodynamically
stable compared with that of wild-type viruses (Fu et al., 2006). It was
demonstrated that these PTAP− particles contained fully processed
Gag products but the viral cores were not condensed and the virions
maintained an immature morphology (Demirov et al., 2002; Huang et
al., 1995). These results suggest that core condensation is associated
with RNA maturation. In the current study, many of the protease
inhibitor-treated viruses had an aberrant, mature phenotype (Figs. 5B
and C). It was unclear how this aberrant morphologywould affect RNA
maturation. Viral RNA maturation could be impeded because a
condensed core was not formed; alternatively, a condensed area was
detected within the viruses, albeit not in the core, which might have
been the result of core-independent RNA maturation.
To explore these possibilities, we next determined the effect of
protease inhibitor treatment on maturation of the genomic RNA
within the virions. The RNA was extracted from the released virions
and separated by native gel electrophoresis. Genomic RNA was
detected by northern analysis with probes generated from a DNAFig. 6. Effects of protease inhibition on HIV-1 RNAmaturationwithin the viral particles. Virion
northern blotting using gag-speciﬁc, 32P-labeled riboprobes. (A) Representative northern
Thermodynamic stability of the virion RNA dimer. Intensities of the dimeric and monomeric
the RNA samples were treated prior to gel electrophoresis; y-axis, the percentage of RNA
independent experiments are shown.fragment containing HIV-1 gag sequences. To measure the stability of
the dimeric species, the RNA was heated for 10 min prior to gel
electrophoresis at various temperatures between 25 °C and 80 °C.
Nondenatured wild-type viral RNA migrated as a dimeric species (Fig.
6A, WT 25 °C). With a sufﬁcient increase in temperature (~54 °C for
wild-type viral RNA), the dimer began to dissociate into its monomeric
constituents (Fig. 6A, WT 54–60 °C). Once dissociated from the dimer,
a portion of the monomeric RNA molecules appeared fragmented,
migrating as a smear beneath the intact full-length monomer (Fig. 6A,
WT 80 °C). In the absence of protease activity, not only is the viral
morphogenesis inhibited but the genomic RNA does not adopt the
tight dimeric species observed in mature wild-type virus. Instead the
RNA migrates as two species (Fig. 6A, PR− 25 °C). The ﬁrst species is a
loosely associated dimer that migrates slightly slower than themature
dimer and dissociates into its monomeric constituents at a much
lower temperature compared with wild-type virus (Fig. 6A, observe
WTand PR− at 54 °C) (Fu, Gorelick, and Rein,1994). The second species
migrates with the samemobility as full-length monomeric RNA and is
assumed to be the product of previously dissociated weak dimers.
Northern analyses of RNA samples isolated from virions treated
with protease inhibitors at IC50 concentrations demonstrated that the
virion RNAs were dimeric (Fig. 6A). Furthermore, the thermodynamic
stability of these RNA samples was similar to that of the wild-type
viral RNA samples isolated from untreated virions (Figs. 6A and B),RNAwas isolated, heated to the indicated temperature, and analyzed by nondenaturing
analyses of RNA samples isolated from wild-type, drug-treated, and PR− samples. (B)
RNA signals were quantiﬁed using a phosophorimager. X-axis, the temperature at which
dimer detected in the total signal. Means and standard errors generated from three
158 M.D. Moore et al. / Virology 379 (2008) 152–160even though approximately 40k of these protease inhibitor-treated
virions displayed an aberrant morphology without an electron-dense
core (Fig. 5C, IC50 samples). Northern analyses of samples from
virions treated with IC90 concentrations of drugs revealed that most
of the virion RNA remained dimeric, although there was a slight
increase (~5k) in monomeric RNA; the thermodynamic stability of
these RNA samples was slightly reduced (2–3 °C) compared with
that of wild-type samples. These protease inhibitor-treated virions
had large populations of morphologically aberrant virions that
contained condensed patches without the electron-dense conical
cores (40–60k, Fig. 5C), and yet the thermodynamic stability of their
RNAs resembled that of the wild-type viruses. Taken together, these
results suggest that RNA maturation can occur without the correct
viral core formation.
Discussion
Protease inhibitors are a major weapon in the ﬁght against HIV-1
infection. Although their target, the viral protease, and their mode of
action have been well studied, very little is known about the overall
effects of the drugs on the virus itself. Clearly, the viral protease is an
essential element because in its absence, HIV-1 particles are
noninfectious (Kohl et al., 1988). However, following the introduction
of protease inhibitors, it became clear that only minor inhibition of the
protease, as judged by the amounts of cleavage products, is sufﬁcient
to have catastrophic effects on the level of viral infectivity (Kaplan et
al., 1993). The lack of a distinct mechanism for this nonlinear
relationship between protease inhibition and antiviral activity led to
their hypothesis that the proteolytic cleavage events are sequentially
and temporally regulated; a slight alteration in this proteolytic
cascade results in a disproportionate effect on the ability of the
virus tomature and become infectious (Pettit et al., 2005a; Pettit et al.,
2004). However, because the impact of this cascade on the
conformation of the viral RNA had not previously been investigated,
we set out to address the possibility of a link between protease
inhibition and RNA maturation.
In this report, we probed the mechanisms of virion maturation by
treating HIV-1 with suboptimal doses of protease inhibitors. In
agreement with previous studies, we observed that most of the Gag/
Gag–Pol polyproteins were cleaved even in the IC90 samples. We also
observed that many of the particles exhibited an aberrant mature
phenotype; these morphologically aberrant viruses occupied more
than 50k of the viral population in the IC90 groups. Intriguingly, our
analyses revealed that viral RNAs isolated from drug-treated viruses
had mostly mature, stable RNA dimers, suggesting that virion RNA
maturation is able to occur despite the aberrant morphology. Our
previous study of PTAP− mutant viruses provides a contrast to the
current study of protease inhibitor-treated viruses. Similar to the
drug-treated viruses, most of the Gag/Gag–Pol processing was
complete in the PTAP− virions; however, the morphology of PTAP−
virions remained immature and the virion RNAs had a much lower
thermodynamic stability than the wild-type virus RNAs. In protease
inhibitor-treated samples, there were patches of condensed regions.
We speculate that during the generation of these condensed regions,
RNA maturation was allowed to occur despite the lack of a proper
conical core.
Our current understanding supports the idea that after proteolytic
cleavage, the CA proteins refold and reorganize into a conical core,
which at least in part transforms the virion from an immature to
mature form. Although the framework of CA–CA interactions that
allows the core formation has been largely elucidated (Li et al., 2000;
von Schwedler et al., 1998; von Schwedler et al., 2003), little is known
about elements that can promote or inhibit virus maturation. It has
been shown that only a portion (V50k) of the HIV-1 mature CA
proteins is incorporated into the core structure itself (Briggs et al.,
2004; Lanman et al., 2004). In the protease inhibitor-treated samples,most of the virion proteins were processed (Fig. 3C), which should
have provided sufﬁcient amounts of CA to form a proper core.
However, our EM analyses demonstrated that a large percentage of
the virions had an aberrant morphology and lacked a condensed core
(Fig. 5). The bcascadeQ theory proposes that the impact of protease
inhibitors on virus morphology is due to an interruption in the ﬁnely
tuned maturation process, which requires only slight alterations to
prevent correct completion (Kaplan et al., 1993; Pettit et al., 2005a).
Therefore, the Gag processing intermediates identiﬁed in this study
would simply be the by-products of the partially active protease. As an
alternative hypothesis, and in line with recent studies, we propose
that it might be the presence of the processing intermediates
themselves, admittedly in small quantities, that is responsible for
the subsequent inhibition of infectivity and maturation. These
intermediate proteins might, in fact, be acting as dominant-negative
inhibitors of successful maturation. Two precedents for processing
intermediates acting in such a manner have been shown recently:
MA–CA of murine leukemia virus (MLV), and CA–SP1 of HIV-1. A
processing mutant of MLV Gag that prevented cleavage at the MA–CA
border (Oshima et al., 2004) was noninfectious and incapable of
completing maturation; furthermore, the MA–CA protein was also a
potent dominant-negative inhibitor of maturation and infectivity of
wild-type virus (Rulli et al., 2006). An MA–CA cleavage mutant has
also recently been demonstrated to have dominant-negative effects
on HIV-1 maturation (S.-K. Lee and R. Swanstrom, personal commu-
nication). A recently developed HIV-1 inhibitor, PA-457 or bevirimat,
targets the CA–SP1 cleavage site to prevent virion maturation (Li et al.,
2003). Notably, small amounts of both the MA–CA and the CA–SP1
intermediates were detected in our protease inhibitor-treated sam-
ples. Therefore, we speculate that part of the mechanism of action for
the protease inhibitors involves generating small amounts of proces-
sing intermediates, which act in a dominant-negative manner to
prevent the formation of mature, infectious virions.
Recent studies suggest that the formation of the mature HIV-1
virion core may be template driven, which could be viral RNA or
component(s) of the membrane (Briggs 2003, 2006, Jensen 2005). In
most of the mature eccentric virions, we observed electron-lucent
core-like structures along with electron-dense regions sequestered on
the side of the particles, suggesting viral RNA might be excluded from
these bcoresQ. This intriguing ﬁnding suggests that partial inhibition of
the protease activity may affect the process required for incorporation
of the viral RNA into the core. Although some of the electron-lucent
bcoresQ in the mature eccentric virions are conical, many cores are
aberrantly shaped (Fig. 5A). We envisioned three possible interpreta-
tions; ﬁrst, the lack of viral RNA could affect the structure of the core,
resulting in aberrantly shaped cores. Secondly, the drug treatment
could affect the template usage such that a different template was
used to drive core assembly, resulting in the exclusion of RNA and the
aberrantly shaped cores. Thirdly, Gag processing intermediates may
be included into the core via CA–CA interactions and lead to a
reduction in core symmetry, thereby resulting in pleomorphic
assembly. Additionally, partially- or unprocessed Gag may remain
associated with the membrane and the RNA, preventing the viral
genome from being incorporated into the core. Further studies of the
mechanisms and requirements of core assembly can verify these
possible interpretations. Interestingly, electron-lucent bcoresQ were
also observed in HIV-1 virions lacking RT-IN (Shehu-Xhilaga et al.,
2002); it is unclear whether a similar mechanism causes the
formation of these cores in both studies.
The currently available antiviral drugs provide signiﬁcant clinical
beneﬁts to HIV-1-infected patients. However, the inevitable emer-
gence of drug-resistant viral variants makes it necessary to continue
the development of new antiviral strategies and compounds. Under-
standing the impact of the antiviral treatment to the virus and its life
cycle can provide insights into the mechanisms of action and possible
novel strategies for new compounds. In this study, we examined the
159M.D. Moore et al. / Virology 379 (2008) 152–160effects of suboptimal protease inhibitor treatment on virus matura-
tion. From our results, we speculate that other strategies similar to
that of bevirimat, might be used to develop antiviral strategies that
block virus maturation via the presence of other processing
intermediates. Furthermore, we also observed that many drug-treated
virions contained core-like structures but with electron-dense
patches on the sides of the virus, suggesting that viral RNA might be
excluded from the core. This observation provides another possible
strategy to develop molecules that can interfere with the inclusion of
viral RNA in the core. Such diversiﬁcation of the strategies available for
the treatment of HIV-1 infection is essential to enhance our ability to
control the replication of the virus.
Materials and methods
Cell culture, viral production, and drug treatment
TZM-bl and 293T cells were maintained at 37 °C in a 5k CO2
environment and cultured in Dulbecco's modiﬁed Eagle's medium
that was supplemented with 10k fetal calf serum, 1k penicillin-
streptomycin, and 1k glutamine. For viral production, 293T cells were
transfected using the TransIT-LT1 reagent (Mirus) with pON-fHIG
(Rhodes et al., 2005), which encodes an env-deﬁcient NL4.3-based
HIV-1 vector, and pIIINL(AD8)env, which encodes HIV-1 env (Huang et
al., 1995). The plasmid pHIV-Pro was used as a control, which encodes
an NL4.3-based virus with an inactivating D25N mutation in the
protease active site (PR–) (Kohl et al., 1988). Various concentrations of
lopinavir (10–80 nM) or atazanavir (2.5–15 nM) were added to the
culture 4 h posttransfection; 24 h later, viral supernatants were
harvested, clariﬁed by ﬁltration through a 0.45-μm-pore-size ﬁlter to
remove cellular debris, and analyzed for infectivity. Serial dilutions of
supernatants from untreated, drug-treated, and PR− viruses were
added to TZM-bl cells (Derdeyn et al., 2000; Wei et al., 2002), a HeLa-
based cell line stably expressing CD4 and CCR5 and containing a
luciferase reporter gene under the transcriptional control of the HIV-1
LTR. Transcription of the luciferase gene was activated by the
expression of Tat from exogenous input virus, thereby providing a
measure of HIV-1 infection. Luciferase expression was measured 72 h
postinfection using a LUMIstar Galaxy (BMG) luminometer after the
addition of Brightlite luciferase solution (Perkin Elmer). Drug
concentrations that approximated IC50 and IC90 were determined by
luciferase activity, and these samples were further analyzed by EM,
western blotting, and northern blotting. In our experiments, the
concentrations that generated IC50 were 27 nM for lopinavir, and
ranged from5.25 to 8.87 nM for atazanavir, whereas the concentration
that generated IC90 ranged from 56 to 76 nM for lopinavir, and 12.5 to
16 nM for atazanavir.
EM, western, and northern analyses
Viral pellets were obtained by ultracentrifugation of clariﬁed viral
supernatants at 100,000 g for 1 h at 4 °C. Transfected cells and viral
pellets were washed once in phosphate-buffered saline, then ﬁxed in
2k glutaraldehyde in 0.1 M sodium cacodylate (pH 7.4) for 20 min at
room temperature prior to processing. EM analysis was performed as
previously described (Tobin et al., 1996).
For western analyses, viral pellets were resuspended in loading
buffer (Invitrogen), and proteins were separated by electrophoresis on
a 12k Tris–glycine gel and transferred to an immobilon-FL PVDF
membrane (Millipore). The membrane was treated with human anti-
HIV-1 antisera at a 1:25,000 dilution and rabbit anti-RT antibody at a
1:4000 dilution (both antibodies were obtained from the NIH AIDS
Research and Reference Reagents Program). Signal detection was
achieved using donkey anti-human antibodies labeled with the
IRDye800 ﬂuorophore and goat anti-rabbit antibodies labeled with
the IRDye680 ﬂuorophore. Integrated ﬂuorescent intensities weremeasured using an Odyssey infrared imaging system (Li-Cor) with the
background subtracted by the median border method.
Virion RNA isolation and nondenaturing northern blotting were
performed using previously described procedures (Fu and Rein, 1993;
Khandjian and Meric, 1986). The membrane was hybridized with 32P-
labeled riboprobes containing HIV-1 gag sequences. Signal intensities
were measured using a phosphorimager and QuantityOne version 4.5
software (BioRad).
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